P. J. M. Brouwer

The paper structures and characterizes Lassa virus glycoproteins from multiple lineages and identifies neutralizing antibodies that target conserved epitopes.

This study develops Lassa virus glycoprotein nanoparticles that stabilize GPC trimers and elicit neutralizing antibodies targeting a new vulnerability site.

This study shows SARS-CoV-2 does not activate dendritic cells via extracellular TLRs but instead relies on intracellular sensors after infecting ACE2-expressing dendritic cells.

This study uses single particle mass analyses to examine antibody binding to the SARS-CoV-2 spike protein, revealing sub-stoichiometric binding and its effectiveness in blocking ACE2.

This study detects S-protein and RBD-specific antibodies in saliva from mRNA-vaccinated healthcare workers after their second dose.

The paper compares glycosylation patterns of recombinant SARS-CoV-2 spike proteins across labs with infectious virus S protein, finding conserved site-specific glycan maturation stalling linked to protein structure.

This study shows that displaying HIV-1 Env trimers on two-component protein nanoparticles enhances autologous Tier-2 neutralizing antibody titers in rabbits.

This paper develops a two-component spike nanoparticle vaccine that protects macaques from SARS-CoV-2 infection by inducing strong neutralizing antibodies and reducing viral replication.

The paper identifies a SARS-CoV-2 antibody that cross-neutralizes SARS-CoV by binding a conserved epitope and relies on avidity for neutralization.

This study identifies an alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 RBD, showing that longer CDR H3 can bind with different angles and interactions.

The paper shows that afucosylated IgG responses are common in enveloped virus infections and are more severe in COVID-19, with implications for immune response and pathology.